WEDNESDAY, 19th JUNE 2019 COMMENCING 10:30 AM
AT THE COPTHORNE HOTEL CARDIFF, COPTHORNE WAY, CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting 1/AWSMG/0619

5. Chairman’s report (verbal update)

6. Appraisal 1: Limited Submission
   Rufinamide (Inovelon®) adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 year of age to less than 4 years of age 2/AWSMG/0619

7. Appraisal 2: Limited Submission
   Eslicarbazepine acetate (Zebinix®) adjunctive therapy in adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations 3/AWSMG/0619

8. AWMSG appraisal process for medicines for rare diseases 4/AWSMG/0619

Date of next meeting – Wednesday, 17th July 2019 in Cardiff